Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Takeda and Orexigen announce availability of weight management tablets in US

Takeda Pharmaceutical Company Limited, its wholly-owned subsidiary Takeda Pharmaceuticals USA., Inc. and Orexigen Therapeutics, Inc., a developer of drug treatments for obesity and related disorders, have announced the availability of Contrave extended-release tablets for chronic weight management to patients by prescription in pharmacies across the US.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Valeant Pharmaceuticals reports net income for Q3

Valeant Pharmaceuticals International, Inc. has reported that net income attributable to the company for the third quarter ended September 30, 2014 was $275.4 million, or $0.81 per diluted share, compared to a net loss attributable to the company of $973.2 million, or $2.92 loss per diluted share, for the same quarter ended September 30, 2013.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Medtronic introduces titanium coated interbody fusion devices for spine

Medtronic, Inc., a medical technology company, has introduced its Pure Titanium Coating, or PTC, platform of interbody fusion devices for the spine, which includes the CAPSTONE PTC Spinal System, CLYDESDALE PTC Spinal System, ANATOMIC PEEK PTC Cervical Fusion System and CORNERSTONE-SR Ti- Coated Anatomical Cervical Cage.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

HealthStream Q3 net income up

HealthStream, Inc., a provider of software-as-a-service solutions for the healthcare industry, has reported a net income of $3.44 million, or $0.12 per share, for the third quarter ended September 30, 2014, compared to $2.30 million, or $0.08 per share, for the same quarter ended September 30, 2013.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Immunomedics receives orphan drug status from EMA for pancreatic cancer drug

Immunomedics, Inc., a clinical-stage biopharmaceutical company, has received orphan drug status from the European Medicines Agency, or EMA, for one of the company's solid-tumor antibody-drug conjugates, or ADCs, isactuzumab govitecan, or IMMU-132, for the treatment of pancreatic cancer.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Peninsula launches health plan for Aboriginal and Torres Strait Islander people

Peninsula Health, a not-for-profit health care group, has launched a Reconciliation Action Plan to reportedly address the factors that contribute to poor health outcomes for Aboriginal and Torres Strait Islander people on the Mornington Peninsula.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Illumina reports higher Q3 net income, provides annual guidance

Illumina, Inc., a developer of life science tools and integrated systems for the analysis of genetic variation and function, has reported that net income for the third quarter ended September 28, 2014 was $93.49 million, or $0.63 per diluted share, compared to $31.36 million, or $0.22 per diluted share, for the same quarter ended September 29, 2013. For fiscal 2014, the company expects non-GAAP earnings per fully diluted share to be in the range of $2.63 to $2.65.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Medtronic launches anterior cervical fusion system in US

Medtronic, Inc., a medical device company, has announced the US launch of the DIVERGENCE Anterior Cervical Fusion System for the treatment of single-level cervical disc disease.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Auxilium's sBLA for treatment of Dupuytren's contracture receives FDA approval

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, has received the FDA approval for supplemental biologics application, or sBLA, for XIAFLEX for the treatment of up to two Dupuytren's contracture, or DC, joints in the same hand during a single treatment visit.

Published By MarketLine
23 Oct 2014
NewsWire
NewsWire

Dexcom receives FDA approval for CGM remote mobile communications device

Dexcom, Inc., a developer of continuous glucose monitoring, or CGM, systems for patients with diabetes, has received FDA approval for its CGM remote mobile communications device, Dexcom SHARE.

Published By MarketLine
23 Oct 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.